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I
n 1956, the German biochemist 
and Nobel Laureate Otto Warburg 
proposed that cancer is caused by 
altered metabolism and by deranged 
energy processing in mitochondria 
[1]. After falling on deaf ears for 
decades, his theory has recently 
enjoyed a resurrection, coinciding 
with an explosion of new information 
on the role of mitochondria in energy 
metabolism and oxygen sensing.
Mitochondrial Enzyme Deﬁ  ciencies 
in Inherited Neoplasia
Mitochondrial defects have 
been associated with severe 
neurodegenerative disorders [2], 
and, more recently, with primary 
hereditary neoplasias. Germline 
heterozygote mutations in the 
nucleus-encoded mitochondrial 
succinate dehydrogenase (SDH) 
subunits—a tricarboxylic acid cycle 
(TCA) enzyme, which is also part 
of the respiratory chain—cause 
inherited pheochromocytomas 
and paragangliomas. Mutations in 
another TCA enzyme, fumarate 
hydratase (FH), cause cutaneous and 
uterine leiomyomas, as well as renal 
cell carcinomas [3]. Mitochondrial 
proteins may also play a role in the 
development of the sporadic kidney 
tumor oncocytoma [4]. Selak et al. has 
recently shed light on the mysterious 
connection between tumors and SDH/
FH [5]; they showed that the hypoxia-
inducible factor (HIF)–mediated 
signaling pathway, known to be 
tumorigenic in von Hippel Lindau 
syndrome, also plays a role in SDH and 
FH deﬁ  ciency (Figure 1) [5].
Somatic mtDNA Mutations 
in Sporadic Tumors
Mitochondrial DNA (mtDNA) 
mutations have also been linked to 
nonhereditary tumors. Intragenic 
deletions (see Glossary) [6], missense 
and chain-terminating point mutations 
[7], and alterations of homopolymeric 
sequences [8] have been identiﬁ  ed 
in nearly every type of tumor. 
Mutations have been described in 
the hypervariable regions of the 
mitochondrial D-loop, the section of 
DNA controlling mtDNA transcription 
and replication that is most prone to 
mutation. Mutations have also been 
described in all 22 tRNAs, both rRNAs, 
and all 13 of the mtDNA-encoded 
subunits of the respiratory chain 
complexes.
These ﬁ  ndings pose a key conceptual 
question: how do these mutations 
arise and then establish themselves 
so quickly in the tumor? Many of the 
(noninherited) mtDNA mutations lead 
to the mtDNA of the tumor becoming 
heteroplasmic; i.e., they are a mixture 
of normal germline mtDNAs found in 
the noncancerous tissue and mtDNAs 
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Figure 1. Schematic Model for Tumorigenesis in SDH deﬁ  ciency
SDH is a component of the OxPhos complexes (I–IV) as well as the TCA cycle. Due to SDH deﬁ  ciency 
succinate accumulates intramitochondrially (the same occurs when FH is deﬁ  cient) and is 
transported into the cytosol. Here, its elevated concentration inhibits prolyl hydroxylases (PDH1-
3), which can no longer degrade HIF-1α even under normoxic conditions. Heterodimerisation of 
stabilized HIF-1α and HIF-1β now forms HIF, which induces transcription of nuclear genes involved 
in tumor progression [5]. 
(Illustration: Giovanni Maki) PLoS Medicine  |  www.plosmedicine.org 1083
containing one or more mutations. Even 
more surprising than this heteroplasmy 
is the observation that most mutations 
are apparently homoplasmic (i.e., there 
is no evidence of the germline mtDNA 
haplotype in the tumor), and further, 
some of those genomes contain not one, 
but two, three, and even four mutations, 
all on the same mtDNA circle. How can 
a cell with mitochondrial haplotype 
A in noncancerous tissue shift its 
mitochondrial genotype to haplotype 
B so rapidly in the adjacent tumor? 
Mathematical models of heteroplasmic 
shifting in rapidly dividing tumor 
cells [9] have been invoked to explain 
this conundrum, but the mechanism 
of shifting remains both elusive and 
controversial.
In this issue of PLoS Medicine, Salas 
et al. question the very foundation 
of the observation of haplotype 
shifting in tumors [10]. They present 
evidence that much of the literature 
demonstrating mutations—whether 
heteroplasmic or homoplasmic—has 
been laden with technical and 
conceptual errors that reduce the 
ﬁ  nding of mtDNA mutations in tumors 
to the level of technical artifact. 
Salas et al. rightly emphasize the 
importance of the highest standards 
in mtDNA analysis to produce reliable 
results in the many investigations on 
this subject [10]. In summary, they 
point out that double-checking to avoid 
sample mix-ups and using stringent 
procedures to extract either puriﬁ  ed 
mtDNA or total DNA containing the 
mtDNA will guarantee high-quality 
templates (avoiding, for example, 
ampliﬁ  cation of nuclear mitochondrial 
pseudogenes, as in the criticized 
study of Reddy et al. [11]). They also 
point out that controls should be 
ethnicity- and age-matched, and that 
every mutation should be checked 
to see whether the mutation is listed 
in the Mitomap database or is an 
ethnic-speciﬁ  c haplotype-deﬁ  ning 
polymorphism. Furthermore, when 
interpreting results, researchers 
should assess whether the missense 
mutations that are being implicated 
in carcinogenesis fulﬁ  ll the criteria 
for pathogenicity (for example, they 
should occur in highly conserved 
regions or destroy structurally 
important motifs). If these criteria are 
adhered to, Salas et al. claim that the 
vast majority of mtDNA mutations in 
tumors will simply disappear [10].
However, although technical errors 
probably do account for some of 
the positives found in some of the 
literature, they cannot account for 
all of them. Putting aside the issue 
of mechanism, the question that 
remains—can mtDNA haplotypes shift 
rapidly in tumors—is not only still with 
us, but is almost certainly answered 
afﬁ  rmatively. 
We would interpret the mtDNA 
sequencing data from the phylogenetic 
point of view differently than Salas 
and colleagues. mtDNA haplotype-
specifying polymorphisms [12] 
arising on a background of a ﬁ  xed 
mitochondrial germline haplotype 
are seen commonly in tumors, 
for example, in a patient with 
myelodysplastic syndrome ([MDS], 
case one in [13]) who had mtDNA 
germline haplotype U (conﬁ  rmed 
by U-specifying polymorphisms at 
nt 150, 3197, 12308, and 12372). 
Such polymorphisms are not 
necessarily due to sequencing errors 
or contaminations. The typical slow 
progression of MDS to acute leukemia 
in this patient made it possible to 
monitor the shift from “initial” 
germline homoplasmy to heteroplasmy 
to “ﬁ  nal” homoplasmy of mutated 
mtDNA in the tumor in different stages 
of the disease. Figure 2 shows that the 
haplotype U–specifying positions 12308 
and 12372 in the patient’s platelets 
had a “beginning” heteroplasmy in 
MDS (Figure 2A), which reached 
more than 50% when the cells were 
in transformation (Figure 2B), and 
“ended” at homoplasmy when the 
acute leukemia arose (Figure 2C). 
Sample contamination or a shift from 
haplotype U to H can be excluded here 
because all other haplotype-speciﬁ  c 
polymorphisms were homoplasmic for 
type U, not H. The same observation 
was made in patient 2 of the cited 
study from Kirches et al. [14]. This 
patient had a germline mitochondrial 
haplotype J, which “shifted” in 
positions 185, 295, and 16126 back to 
the phylogenetically older haplotype H, 
but shifted in position 195 to haplotype 
W and in position 204 to nowhere.
Although the mechanism of 
rapid shifting is still unclear, 
random processes, extensively 
modeled in computer systems [9], 
may well explain the presence of 
homoplasmic mutations in cancer. 
It may be that certain mitochondrial 
haplotypes or pathogenic mutations 
represent a selective advantage in 
tumor progression, similar to the 
overrepresentation of haplotype J seen 
in Leber hereditary optic neuropathy, 
a maternally inherited mitochondrial 
disease [15].
Challenges for the Future
Warburg was right. One can no longer 
ignore mitochondria in cancer biology. 
Mutations of mtDNA, even driven by 
random processes during malignant 
transformation, present an excellent 
possibility for early tumor detection 
using, e.g., D-loop analysis of bodily 
ﬂ  uids from patients with tumors [16]. 
(As an aside, direct sequencing of 
tumor mtDNA, as performed by many 
groups, is a poor screening technique, 
as it misses levels of heteroplasmy below 
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Figure 2. Mutations C12308T and T12372C
Alter Polymorphisms Specifying European 
Mitochondrial Haplotype U
Mutation load in (A) MDS, (B) MDS in 
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approximately 20%; a better method 
is denaturing high-performance 
liquid chromatography followed 
by conﬁ  rmatory polymerase chain 
reaction/restriction fragment length 
polymorphism analysis.) 
The proposal that mtDNA mutations 
and respiratory dysfunction may be 
linked directly to carcinogenesis 
via apoptotic or reactive oxygen 
species (ROS)–mediated pathways 
is challenging, but urgently needs 
experimental proof. Questions 
regarding whether the HIF-mediated 
pathway is also initiated in hypoxia 
and mitochondrial deﬁ  ciency [17], 
both characteristics of tumors, also 
need to be clariﬁ  ed. If these pathways 
are conﬁ  rmed as being involved in 
tumorigenesis, metabolic targeting 
(e.g., blocking the HIF-pathway by 
administration of α-ketoglutarate) 
of the mitochondrion in cancer may 
open up new avenues to antineoplastic 
therapies and prevention of cancer.  
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Glossary 
Chain-terminating point mutation:
A point mutation that leads to a 
premature stop codon
D-loop analysis: Analysis of 
polymorphisms in the mtDNA control 
region, known as the D-loop
Ethnic-speciﬁ  c haplotype-deﬁ  ning 
polymorphism: A polymorphism 
representing an mtDNA variant found 
exclusively in a speciﬁ  c population. 
Haplotypes H, K, J, and U are found in 
European populations
Homopolymeric sequences:
Consecutive runs of the same nucleotide
Intragenic deletion: Loss of a 
contiguous segment of DNA from a gene
Missense mutation: A point mutation in 
a codon resulting in the alteration of one 
encoded amino acid to another
Mitomap database: An online human 
mitochondrial genome database (http://
www.mitomap.org/)
Nuclear mitochondrial pseudogenes:
Nuclear DNA sequences homologous 
to mtDNA sequences, but without any 
function
ROS: Reactive oxygen species
rRNA: Ribosomal RNA
tRNA: Transfer RNA
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